Short-term itraconazole versus terbinafine in the treatment of superficial dermatomycosis of the glabrous skin (tinea corporis or cruris)

European Journal of Dermatology

Volumn 7, Issue 5, 1997, Pages 353-357

  Decroix, Jacques ^a   Fritsch, Peter ^b   Picoto, António ^c   Thurlimann W ^d   Degreef, Hugo ^e  

^a Univ Dept Dermatol and Venereol ^*  (Belgium)

^b Universitatsklinik fuer Dermatologie und Venerologie Innsbruck   (Austria)

^c Centro de Dermatologia Medico Cirurgica   (Portugal)

^d Dermatology Allergy and Immunology FMH   (Switzerland)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Clinical response; Itraconazole; Mycological cure; Short term therapy; Tinea corporis; Tinea cruris

Indexed keywords

ITRACONAZOLE; TERBINAFINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOMYCOSIS; DOUBLE BLIND PROCEDURE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FOLLOW UP; GLABROUS SKIN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYOSITIS; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; RHEUMATOID ARTHRITIS; STRATUM CORNEUM; TINEA CORPORIS; TINEA CRURIS; TREATMENT OUTCOME;

EID: 0030835987     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Roberts SOB. Treatment of superficial and subcutaneous mycoses. In: Speller DCE, ed. Antifungal chemotherapy. Chichester, UK: John Wiley, 1980; 255-83.
2. Davies RR, Everall JD, Hamilton E. Mycoloqical and clinical evaluation of griseofulvin for chronic onychomycosis. Br Med J 1967; iii: 464-8.
3. Beghin D, Vanbreuseghem R. Traitement des dermatophyties du cuir chevelu par une dose unique de griseofulvine : essai d'une reduite. Ann Soc Belg Med Trop 1984; 54: 477-81.
4. Levine H, ed. Ketoconazole in the management of fungal disease. Hong Kong: Adis Press, 1982.
5. Cauwenbergh G. New and prospective developments in antifungal drugs. Acta Derm Venereol 1986; 121: 147-53.
6. Heiberg JK, Svejgaard E. Toxic hepatitis during ketoconazole treatment. Br Med J 1981; 283: 825.
7. Santen RJ, Vanden Bossche H, Symoens J, Brugmans J, De Coster R. Site of action of low-dose ketoconazole on androgen biosynthesis in man. J Clin Endocrinol Metab 1983; 57: 732-6.
8. Stevens DA, Williams PL, Sugar AM, Pont A. Ketoconazole effects. Ann Intern Med 1982; 97: 284-5.
9. Cauwenbergh G. Safety aspects of ketoconazole, the most commonly used systemic antifungal. Mycoses 1989; 32 (suppl. 2): 59-63.
10. Heeres J, Backx JJJ, Van Cutsem J. Antimycotic azoles. 7. Synthesis and antifungal properties of a series of novel triazol-3-ones. J Med Chem 1984; 27: 894-900.
11. Vanden Bossche H. Biochemical targets for antifungal derivatives: hypothesis on the mode of action. In: McGinnis MR, ed. Current topics in medical mycology. New York: Springer-Verlag, 1985; 313.
12. Vanden Bossche H, Bellens D, Cools W, Gorrens J, Marichal P, Verhoeven H, Willemsens G, De Coster R, Beerens D, Haelterman C, Coene M-C, Lauwers W, Le Jeune L. Cytochrome P450: target for itraconazole. Drug Dev Res 1986; 8: 287-98.
13. Vanden Bossche H, Marichal P, Gorrens J, et al. Biochemical approaches to selective antifungal activity. Focus on azole antifungals. Mycoses 1989; 32 (suppl. 1): 35.
14. Thienpont D, Van Cutsem J, Borgers M. Ketoconazole in experimental candidosis. Rev Infect Dis 1980; 2: 570-7.
15. Van Cutsem J, Van Gerven F, Janssen PAJ. The in vitro and in vivo antifungal activity of itraconazole. In: Fromtling RA, ed. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona, Spain: JR Prous, 1987; 177-92.
16. Sobel JD, Muller G. Comparison of itraconazole and ketoconazole in the treatment of experimental Candida vaginitis. Antimicrob Agents Chemother 1984; 26: 266-7.
17. Cauwenbergh G, de Doncker P. Itraconazole (R 51211): a clinical review of its antimycotic activity in dermatology, gynecology and internal medicine. Drug Dev Res 1986; 8: 317-23.
18. Heykants J, Michiels M, Meuldermans W, Monbaliu J, Lavrijsen K, Van Peer A, Levron J, Woestenborghs R, Cauwenbergh G. The pharmacokinetics of itraconazole in animals and man: an overview. In: Fromtling RA, ed. Recent trends in the discovery, development and evaluation of antifungal agents. Barcelona, Spain: JR Prous Science Publishers, 1987; 223-49.
19. Larosa E, Cauwenbergh G, Cili P, Woestenborghs R, Heykants J. Itraconazole pharmacokinetics in the female genital tract: plasma and tissue levels in patients undergoing hysterectomy after a single dose of 200 mg of itraconazole. Eur J Obstet Gynecol Reprod Biol 1986; 23: 85-9.
20. Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J Am Acad Dermatol 1988; 18: 263-9.
21. Ryders NS. The mechanism of action of terbinafine. Clin Exp Dermatol 1989; 14: 98-100.
22. Villars W, Jones TC. Special features of the clinical use of oral terbinofine in the treatment of fungal diseases. Br J Dermatol 1992; 126 (suppl. 39): 61-9.
23. Arenas R, Dominguez-Cherit J. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol 1995; 34: 138-43.
24. Faergemann J, Zehender H, Millerioux L. Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days. Clin Exp Dermatol 1994; 19: 121-6.
25. Farag A, Taha M, Halim S. One-week therapy with oral terbinafine in cases of tinea cruris/corporis. Br J Dermatol 1994; 131: 684-6.
26. Piérard GE, Arrese JE, de Doncker P. Antifungal activity of itraconazole and terbinafine in human stratum corneum: a comparative study. J Am Acad Dermatol 1995; 32: 429-35.
27. De Doncker P, Cauwenbergh G. Management of fungal skin infections with 15 days itraconazole treatment: a worldwide review. Br J Clin Pract 1990; 44: 118-22.
28. Roseeuw D, Willemsen M, 'T Kint R, Peremans W, Mertens RU, Van Cutsem J. Itraconazole in the treatment of superficial mycoses - a double-blind study versus placebo. Clin Exp Dermatol 1990; 15: 101-4.
29. Degreef H, Marien K, de Veylder H, Duprez K, Borghys A, Verhoeve L. Itraconazole in the treatment of dermatophytosis: a comparison of two daily dosages. Rev Infect Dis 1987; 9 (suppl. 1): S104-S8.
30. Cauwenbergh G, de Doncker P, Stoops K, de Dier AM, Goyvaerts H, Schuermans V. Itraconazole in the treatment of human mycoses: review of three years of clinical experience. Rev Infect Dis 1987; 9: 146-52.